Search | Clinical Trials Finder

Conditions: Social Anxiety Disorder
Interventions: Paroxetine, Cognitive behavioral therapy (CBT); Drug · Behavioral
Lead sponsor: Temple University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2008
U.S. locations: 2
States / cities: New York, New York • Philadelphia, Pennsylvania

Conditions: Major Depressive Disorders
Interventions: amibegron (SR58611A), placebo, paroxetine; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 306 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2004
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Major Depressive Disorder
Interventions: mixed salts amphetamine; Drug
Lead sponsor: Rush University Medical Center; Other
Eligibility: 18 Years to 70 Years
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Stress Disorders, Post-Traumatic, Sleep Disorders
Interventions: prazosin, paroxetine, Placebo; Drug
Lead sponsor: Seattle Institute for Biomedical and Clinical Research; Other
Eligibility: 18 Years to 50 Years
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2008
U.S. locations: 2
States / cities: Washington D.C., District of Columbia • Fort Lewis, Washington

Conditions: Depressive Disorder, Major
Interventions: saredutant (SR48968), paroxetine, placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 825 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Major Depressive Disorder, Partner Relational Disorder (V61.10)
Interventions: Weekly marital therapy, As indicated: Sertraline, bupropion, venlafaxine, mirtazepine, nortriptyline, tranylcypromine, lithium augmentation, etc.; Behavioral · Drug
Lead sponsor: Duke University; Other
Eligibility: 60 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Tobacco Use Disorder
Interventions: Paroxetine, Placebo; Drug
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years to 65 Years
Enrollment: 105 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2010
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Anxiety Disorders
Interventions: SSR149415, Placebo, Paroxetine; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 325 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Postmenopausal Symptoms
Interventions: Brisdelle (paroxetine mesylate); Drug
Lead sponsor: Noven Therapeutics; Industry
Eligibility: 40 Years and older · Female only
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Major Depressive Disorder
Interventions: Brexpiprazole, Antidepressant therapy; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 1,149 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Hot Flashes
Interventions: Brisdelle (paroxetine mesylate), Placebo capsules; Drug
Lead sponsor: Noven Therapeutics; Industry
Eligibility: 40 Years and older · Female only
Enrollment: 570 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 32
States / cities: Montgomery, Alabama • Chandler, Arizona • San Diego, California + 28 more

Conditions: Healthy Volunteers
Interventions: Vortioxetine, Paroxetine, Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 40 Years
Enrollment: 361 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 15
States / cities: Encino, California • Long Beach, California • Torrance, California + 12 more

Conditions: Major Depressive Disorder
Interventions: Levomilnacipran ER, Paroxetine, Sertraline, Citalopram or Fluoxetine., Placebo; Drug
Lead sponsor: Forest Laboratories; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 262 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 20
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Cerritos, California + 17 more

Conditions: Pain, Depression
Interventions: Stepped Care, Antidepressants, Usual Care; Behavioral · Drug
Lead sponsor: Indiana University; Other
Eligibility: 18 Years and older
Enrollment: 500 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2008
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Major Depressive Disorder
Interventions: FDA-approved selective-serotonin reuptake inhibitors (SSRIs) and selective-norepinephrine reuptake inhibitors (SNRIs); Drug
Lead sponsor: Adams Clinical; Network
Eligibility: 18 Years and older
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Watertown, Massachusetts

Conditions: Social Anxiety Disorder, Social Phobia, Alcohol Use Disorder, Alcohol Abuse, Alcohol Dependence
Interventions: Paroxetine, Placebo; Drug
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 18 Years to 65 Years
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2008
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Generalized Anxiety Disorder
Interventions: PD 0332334, paroxetine, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 286 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 27
States / cities: Birmingham, Alabama • Glendale, California • Orange, California + 22 more

Conditions: Healthy
Interventions: Poziotinib, Itraconazole, Phenytoin, Paroxetine; Drug
Lead sponsor: Spectrum Pharmaceuticals, Inc; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 74 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Depressive Disorder, Depression, Depressive Disorder, Major, Mood Disorders, Mental Disorders
Interventions: OPC-34712, Escitalopram, Fluoxetine, Paroxetine CR, Sertraline, Duloxetine, Venlafaxine XR; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 2,944 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2017
U.S. locations: 93
States / cities: Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 90 more

Conditions: Generalized Anxiety Disorder
Interventions: PD 0332334, Paroxetine, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 360 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 29
States / cities: Arcadia, California • Costa Mesa, California • Escondido, California + 25 more

Conditions: Tardive Dyskinesia, Intellectual Disability, Developmental Disabilities
Interventions: Valbenazine Oral Capsule; Drug
Lead sponsor: Stephen Ruedrich; Other
Eligibility: 18 Years to 70 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Depressive Disorder, Major
Interventions: JNJ-42847922, Placebo Matching to JNJ-42847922, Quetiapine XR, Placebo Matching to Quetiapine XR, Selective Serotonin Reuptake Inhibitor (SSRI), Serotonin-Norepinephrine Reuptake Inhibitor (SNRI); Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 107 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 50
States / cities: Phoenix, Arizona • Tempe, Arizona • Rogers, Arkansas + 41 more

Conditions: Depression
Interventions: Placebo, identified as placebo to participants, Celexa or other antidepressant as clinically indicated, Placebo, identifed to participants as "Active medication"; Other · Drug
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years to 60 Years
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Healthy
Interventions: Vilazodone 20 mg, Vilazodone 40 mg, Paroxetine 20 mg, Placebo; Drug
Lead sponsor: Forest Laboratories; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 202 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 4
States / cities: Miami, Florida • Overland Park, Kansas • Saint Paul, Minnesota + 1 more

Search by objective public record fields.

Adding Cognitive Behavioral Therapy to Drug Treatment for Social Anxiety Disorder

Efficacy and Safety of One Single Dose of SR58611 Compared to Placebo and Paroxetine

Adjunctive Mixed Salts Amphetamine for Depressed Adults With Incomplete Response to Current Antidepressant Therapy

Prazosin vs Paroxetine in Combat Stress-Related Post-Traumatic Stress Disorder (PTSD) Nightmares & Sleep Disturbance

An Eight-week Study of Saredutant and Paroxetine as Combination Treatment for Major Depressive Disorder

Treatment of Mood and Marriage Study (TOMMS)

Effect of Paroxetine on Smokers' Cardiovascular Response to Stress - 1

An Eight-week Study Evaluating the Efficacy and Tolerability of Two Doses of SSR149415 in Outpatients With Generalized Anxiety Disorder

Pharmacokinetic Evaluation of Brisdelle™ (Formerly Known as Mesafem) Following Single & Repeat Oral Administration in Healthy Postmenopausal Women

A Trial to Evaluate the Efficacy, Safety & Tolerability of Brexpiprazole in the Maintenance Treatment of Adults With Major Depressive Disorder

24-Week Efficacy & Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms

Effect of Vortioxetine, Paroxetine, and Placebo on Sexual Functioning in Healthy Volunteers

Safety and Efficacy of Levomilnacipran ER (F2695 SR) in Adults With Fatigue Associated With Major Depressive Disorder

Stepped Care for Depression and Musculoskeletal Pain

Tracking Response to Antidepressants in Advance of Investigational Trials

Paroxetine for Comorbid Social Anxiety Disorder and Alcoholism

A 10-week Study Evaluating the Efficacy and Safety of PD 0332334 for the Treatment of Generalized Anxiety Disorder (3)

A Study to Evaluate the Effect of Multiple Doses of Itraconazole, Phenytoin, and Paroxetine on the Single-Dose Pharmacokinetics of Poziotinib in Healthy Adult Participants

Safety and Tolerability of Oral OPC-34712 as Adjunctive Therapy in Adults With Major Depressive Disorder (the Orion Trial)

A 10-week Study Evaluating the Efficacy and Safety of PD 0332334 in Patients With Generalized Anxiety Disorder (2)

Valbenazine Treatment of Tardive Dyskinesia in Adults With Intellectual/Developmental Disabilities

A Study to Compare the Efficacy, Safety, and Tolerability of JNJ-42847922 Versus Quetiapine Extended-Release as Adjunctive Therapy to Antidepressants in Adult Participants With Major Depressive Disorder Who Have Responded Inadequately to Antidepressant Therapy

Predictors of Antidepressant Response

Study to Evaluate the Sexual Functioning of Healthy Adults After Receiving Vilazodone, Paroxetine or Placebo